KR101667534B1 - 리팍시민 - Google Patents

리팍시민 Download PDF

Info

Publication number
KR101667534B1
KR101667534B1 KR1020147026177A KR20147026177A KR101667534B1 KR 101667534 B1 KR101667534 B1 KR 101667534B1 KR 1020147026177 A KR1020147026177 A KR 1020147026177A KR 20147026177 A KR20147026177 A KR 20147026177A KR 101667534 B1 KR101667534 B1 KR 101667534B1
Authority
KR
South Korea
Prior art keywords
rifaximin
amorphous
water
crystalline
washed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147026177A
Other languages
English (en)
Korean (ko)
Other versions
KR20140131543A (ko
Inventor
다르마라즈 라마찬드라 라오
라젠드라 나라얀라오 칸칸
만진더 신그 풀
마루티 가가레
Original Assignee
씨아이피엘에이 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38815026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101667534(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 씨아이피엘에이 엘티디. filed Critical 씨아이피엘에이 엘티디.
Publication of KR20140131543A publication Critical patent/KR20140131543A/ko
Application granted granted Critical
Publication of KR101667534B1 publication Critical patent/KR101667534B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147026177A 2006-09-22 2007-09-24 리팍시민 Active KR101667534B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1520/MUM/2006 2006-09-22
IN1520MU2006 2006-09-22
PCT/GB2007/003629 WO2008035109A1 (en) 2006-09-22 2007-09-24 Rifaximin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097008106A Division KR101480732B1 (ko) 2006-09-22 2007-09-24 리팍시민

Publications (2)

Publication Number Publication Date
KR20140131543A KR20140131543A (ko) 2014-11-13
KR101667534B1 true KR101667534B1 (ko) 2016-10-19

Family

ID=38815026

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147026177A Active KR101667534B1 (ko) 2006-09-22 2007-09-24 리팍시민
KR1020097008106A Active KR101480732B1 (ko) 2006-09-22 2007-09-24 리팍시민

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097008106A Active KR101480732B1 (ko) 2006-09-22 2007-09-24 리팍시민

Country Status (8)

Country Link
US (8) US8633234B2 (https=)
EP (1) EP2069363B1 (https=)
JP (7) JP2010504314A (https=)
KR (2) KR101667534B1 (https=)
AU (1) AU2007298733B2 (https=)
CA (1) CA2663776C (https=)
NZ (1) NZ575550A (https=)
WO (1) WO2008035109A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
KR101667534B1 (ko) * 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
UA113275C2 (xx) 2008-02-25 2017-01-10 ζ-ФОРМА РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ
HUE048293T2 (hu) 2008-10-02 2020-07-28 Salix Pharmaceuticals Ltd Eljárások hepatikus enkefalopátia kezelésére
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
WO2011080691A1 (en) * 2009-12-28 2011-07-07 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
IT1399141B1 (it) * 2010-04-02 2013-04-05 Secci Metodo per la preparazione di rifaximina in stato amorfo.
IT1398550B1 (it) * 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
AU2011225810B2 (en) 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
WO2012035544A2 (en) * 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
SG192122A1 (en) * 2011-02-11 2013-08-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
WO2012150561A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110983A1 (it) * 2011-05-30 2012-12-01 A M S A Anonima Materie Sint & Affini S P A Amorfo di rifaximina e processo per la sua preparazione
WO2013027227A1 (en) * 2011-07-20 2013-02-28 Ind-Swift Laboratories Limited Novel polymorphic form i of rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CA2854380A1 (en) * 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs) and infections
CA2876737A1 (en) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
CN105142636A (zh) 2013-03-15 2015-12-09 意大利阿尔法韦士曼制药公司 用于治疗阴道感染的利福昔明
EP2983647B1 (en) 2013-04-12 2020-09-09 Alfasigma S.p.A. Nsaid administration and related compositions, methods and systems
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
EP3134415A4 (en) * 2014-04-19 2017-10-25 Granules India Limited An improved process for the preparation of rifamycin derivatives
US10685402B1 (en) 2014-04-25 2020-06-16 State Farm Mutual Automobile Insurance Company Systems and methods for homeowner-directed risk of property damage mitigation
NZ723571A (en) 2014-05-12 2020-02-28 Alfasigma Spa New solvated crystal form of rifaximin, production, compositions and uses thereof
MX381919B (es) * 2014-06-30 2025-03-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
US10353359B1 (en) 2014-10-07 2019-07-16 State Farm Mutual Automobile Insurance Company Systems and methods for managing smart devices based upon electrical usage data
WO2016063289A2 (en) * 2014-10-22 2016-04-28 Strides Arcolab Limited Pharmaceutical tablet compositions comprising rifaximin
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
WO2018178777A1 (en) * 2017-03-31 2018-10-04 Granules India Limited Process for the preparation of rifaximin crystalline form
CN111423456A (zh) * 2020-04-03 2020-07-17 南京昊绿生物科技有限公司 一种利福昔明-d6的合成工艺
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CN117447487A (zh) * 2022-07-19 2024-01-26 重庆圣华曦药业股份有限公司 一种利福昔明的纯化方法及其在利福昔明片剂中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044823A2 (en) * 2003-11-07 2005-05-19 Alfa Wassermann S.P.A. Polymorphous forms of rifaximin as antibiotics
WO2008155728A1 (en) * 2007-06-20 2008-12-24 Solmag S.P.A. Process for preparing amorphous rifaximin and the amorphous rifaximin thus obtained

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1294205B1 (it) 1997-07-23 1999-03-24 Farmigea Spa Procedimento per la solubilizzazione in acqua e in veicoli acquosi di sostanze farmacologicamente attive
JPH11246404A (ja) * 1998-03-04 1999-09-14 Taiho Yakuhin Kogyo Kk 吸収を改善した医薬組成物
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2002032459A2 (en) 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by complexing with cyclodextrins
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
US20070082870A1 (en) 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
KR101667534B1 (ko) * 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009137672A1 (en) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044823A2 (en) * 2003-11-07 2005-05-19 Alfa Wassermann S.P.A. Polymorphous forms of rifaximin as antibiotics
WO2008155728A1 (en) * 2007-06-20 2008-12-24 Solmag S.P.A. Process for preparing amorphous rifaximin and the amorphous rifaximin thus obtained

Also Published As

Publication number Publication date
AU2007298733B2 (en) 2012-11-08
US12109200B2 (en) 2024-10-08
NZ575550A (en) 2011-12-22
CA2663776A1 (en) 2008-03-27
US20230116935A1 (en) 2023-04-20
JP2022003052A (ja) 2022-01-11
JP2018127470A (ja) 2018-08-16
KR20090080048A (ko) 2009-07-23
KR101480732B1 (ko) 2015-01-21
US20180235944A1 (en) 2018-08-23
US20200368212A1 (en) 2020-11-26
CA2663776C (en) 2016-01-26
US10702505B2 (en) 2020-07-07
JP2016065058A (ja) 2016-04-28
JP2020128380A (ja) 2020-08-27
US9877953B2 (en) 2018-01-30
JP2022003038A (ja) 2022-01-11
EP2069363B1 (en) 2013-03-20
JP2010504314A (ja) 2010-02-12
US8633234B2 (en) 2014-01-21
EP2069363A1 (en) 2009-06-17
KR20140131543A (ko) 2014-11-13
US20160374999A1 (en) 2016-12-29
WO2008035109A1 (en) 2008-03-27
US20150266898A1 (en) 2015-09-24
JP7346353B2 (ja) 2023-09-19
US20140128419A1 (en) 2014-05-08
US20120116071A1 (en) 2012-05-10
US20090312357A1 (en) 2009-12-17
US9403844B2 (en) 2016-08-02
JP2023078160A (ja) 2023-06-06
AU2007298733A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
KR101667534B1 (ko) 리팍시민
EP1601680B1 (en) Methods of making ferric organic compounds
CN1900077A (zh) 利福昔明的新多晶型形式,它们的制备方法及其在药物制剂中的用途
CA2538546A1 (en) Polymorphic forms of rifaximin, processes for their production and use thereof in medicinal preparations
US20110086871A1 (en) Rifaximin compositions and method of use
WO2012155981A1 (en) New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
JP2011236210A (ja) オメプラゾールのエナンチオマーのマグネシウム四水和物塩を調製するための前駆体相およびその使用
KR100912214B1 (ko) 세프디니르 세슘 염의 결정형
EP2710014B1 (en) Process for the synthesis of rifaximin
WO2006010978A1 (en) Cefdinir polymorphic forms, and imidazole salt
HK1077580B (en) Methods of making ferric organic compounds
JP2010285355A (ja) β−ラクタム化合物の安定形結晶の製法
WO2007016209A2 (en) Pure 1,2-benzisoxazole-3-methane-sulfonic acid sodium salt and purification process

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140919

Application number text: 1020097008106

Filing date: 20090421

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141222

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151027

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160926

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20161013

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20161013

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210927

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20220922

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20230921

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee